Skip to main content

Day: March 24, 2022

Data Storage Corporation Schedules Fiscal 2021 Business Update Conference Call

MELVILLE, N.Y., March 24, 2022 (GLOBE NEWSWIRE) — Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity solutions for disaster-recovery, cloud infrastructure, cyber-security and data analytics solutions, today announced that it plans to host a conference call at 10:00 am ET on Thursday, March 31, 2022 to discuss the company’s financial results for the 2021 fiscal year ended December 31, 2021, as well as corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or for international callers +1 973-528-0011 and using entry code: 283625. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2763/44979, or on the Company’s Investor Relations section of the website, ir.datastoragecorp.com. A...

Continue reading

ibex Unveils Augment by ibex for On-Demand Staff Augmentation and Managed Services

Delivers High-Demand Specialized Talent and Strategic Managed Services Globallyibex Unveils Augment by ibex for On-Demand Staff Augmentation and Managed Services Augment by ibex provides specialized dedicated talent for high-demand professional and administration functions, ranging from IT and engineering to cyber security, marketing, data analytics, and data science.WASHINGTON, March 24, 2022 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement technology solutions, today announced the launch of Augment by ibex, the company’s staff augmentation and managed services offering. Augment by ibex provides specialized dedicated talent for high-demand professional and administration functions, ranging from IT and engineering to cyber security, marketing,...

Continue reading

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Thursday, March 31, 2022 to discuss financial results for the year ended December 31, 2021 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines. To participate in the call, interested...

Continue reading

Canadian nonprofits are investing in digital transformation to drive efficiency and growth, Sage study finds

Pandemic has pushed organizations to seek new ways to work and deliver services TORONTO, March 24, 2022 (GLOBE NEWSWIRE) — Sage (FTSE: SGE), the leader in accounting, financial, HR and payroll technology for small and mid-sized businesses, today released a new study on the Canadian nonprofit sector, Grow Together: How digital transformation empowers Canadian nonprofit organizations to embrace change. The study found that nonprofits have seized the opportunity during the pandemic to rethink and change the way they operate to gain efficiencies and better serve their communities, despite the difficulties caused by COVID-19. Transforming operations to overcome challenges In partnership with Leger, a Canadian research firm, Sage found that 9 in 10 nonprofits consider their digital transformation efforts a top priority to update business...

Continue reading

EVmo Expands Fleet through Agreements with Leading OEMs to Supply Vehicles in Support of Growth Quarterly Plans

LOS ANGELES, March 24, 2022 (GLOBE NEWSWIRE) — EVmo, Inc. (OTC: YAYO) (the “Company’), a leading provider of vehicles to the rideshare and delivery gig economy industry, today announced a agreements with leading automobile manufacturers to supply the Company with approximately 400 new vehicles quarterly. “We are thrilled to have agreements with multiple leading OEMs to provide a steady supply of new vehicles to grow our fleet, an important component of our expansion strategy as we enter new markets in the months ahead,” commented Steven Sanchez, CEO of EVmo. “The commitments for these vehicles were made possible by the non-dilutive financing we announced earlier in March. These agreements give us tremendous confidence in our ability to achieve our goal of adding 400 vehicles to our fleet each quarter during 2022. This month’s order...

Continue reading

Aspo Plc – Managers’ transactions – Arto Meitsalo

Aspo Plc Managers’ transactionsMarch 24, 2022, at 3 p.m. Aspo Plc – Managers’ transactions – Arto Meitsalo  Person subject to the notification requirement Name: Meitsalo Arto Position: Chief Financial Officer Issuer: Aspo Oyj LEI: 7437000TB0GHDHLPX677   Notification type: INITIAL NOTIFICATION Reference number: 7437000TB0GHDHLPX677_20220322131347_2 ____________________________________________   Transaction date: 2022-03-23 Venue not applicable Instrument type: SHARE ISIN: FI0009008072 Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION   Transaction details (1): Volume: 9,900 Unit price: EUR Aggregated transactions (1): Volume: 9,900 Volume weighted average price: EUR   Aspo Plc Rolf Jansson CEO Further information, please contact: Rolf Jansson, CEO, Aspo Plc, +358 400 600 264, rolf.jansson@aspo.com Distribution:...

Continue reading

IQST – iQSTEL Announces 3 Target Acquisitions Expected To Close Next Month

New York, NY, March 24, 2022 (GLOBE NEWSWIRE) — iQSTEL, Inc. (OTCQX: IQST) today announced the company expects to close three acquisitions prior to the end of April 2022.  CEO Leandro Iglesias has issued a update today as part of his regular series of updates detailing the company’s ongoing progress toward its $90 million 2022 annual revenue forecast and uplisting to Nasdaq in the first half of this year. The update is included in its entirety below: Dear Shareholders: The first fiscal quarter of 2022 is drawing to a conclusion and in spite of the prevailing market conditions and world events, I am pleased to share that iQSTEL is well on track to achieve its 2022 objectives.  Nothing is standing in the way of our $90 million 2022 annual revenue forecast or Nasdaq uplisting. Permit me to share some highlights. Our new electric vehicle...

Continue reading

Non-Executive Director – External Appointment

         NON-EXECUTIVE DIRECTOR – EXTERNAL APPOINTMENT London, 24 March 2022 – Endeavour Mining plc (LSE: EDV) (“the Company”) announces, in accordance with UK Listing Rule 9.6.14, that Alison Baker, an independent non-executive director of the Company, has notified the Company that she has been appointed to the board of Capstone Copper Corporation, a company admitted to trading on the Toronto Stock Exchange, with effect from 23 March 2022. CONTACT INFORMATIONEndeavour Mining Martino De CiccioVice President – Strategy & Investor Relations+44 203 640 8665mdeciccio@endeavourmining.com Brunswick Group LLP in LondonCarole Cable, Partner+44 7974 982 458ccable@brunswickgroup.com   Vincic Advisors in TorontoJohn Vincic, Principal+1 647 402 6375john@vincicadvisors.comABOUT ENDEAVOUR MINING PLC Endeavour is one...

Continue reading

InflaRx Reports Full Year 2021 Financial and Operating Results

Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativa Positive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual Meeting Topline data in vilobelimab Phase III trial in severe COVID-19 expected by end of March Both US and EU Phase II trials with vilobelimab in AAV met their objectives Phase II trial with vilobelimab in cSCC enrolling with first efficacy data expected later this year New program, INF904 oral small molecule inhibitor of C5aR, recently introduced Year-end cash and cash equivalents of approximately €26.2 million and financial assets of approximately €84.4 millionJENA, Germany, March 24, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company...

Continue reading

Pieridae Releases Q4 and 2021 Results

Upstream Focused Company with a Viable LNG OptionNew President & COO and CFO Promotions Announced NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN UNITED STATES Key Highlights:Generated $57.7 million Adjusted Funds Flow from Operations1 (“AFFO”) in 2021 an increase of 115% year over year from $26.9 million in 2020 to $57.7 million Generated $84.1 million Net Operating Income1 (“NOI”) in 2021, an increase of 66% year over year, from $50.7 million in 2020 Increased petroleum and natural gas revenue to $334.7 million in 2021 up 41% from $238.1 million in 2020 Production averaged 40,562 barrels of oil equivalent per day (“boe/d”) in 2021 , a marginal decrease from 42,000 boe/d in 2020 in the midst of two planned facility turnarounds or planned maintenance shutdowns The proved developed producing (“PDP”) base...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.